Veratoxin as a New Approach to the Prevention of HIV Infections

The intern will use screening methods to define which gene which are altered in the Jurkat human T cell line following incubation with the Verotoxin B subunit as a means to define the potential mechanism by which this treatment protects these cells from HIV1 infection in vitro. LISI Therapeutics will benefit by increasing their license portfolio to include the rights of Verotoxin B subunit as a potential clinical treatment for HIV/AIDS.

Faculty Supervisor:

Dr. Clifford A. Lingwood

Student:

Pei Lin Shi

Partner:

LISI Therapeutics

Discipline:

Biochemistry / Molecular biology

Sector:

Pharmaceuticals

University:

University of Toronto

Program:

Accelerate

Related projects

Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.

View all
Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects

Mitacs Partners

The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.

Government
Academic
Industry
Innovation

International

Load More

International

Load More

Join a thriving innovation ecosystem.

Subscribe to our newsletter now!

Subscribe
Canada